Business context and reporting period
The supplied filing is MEI Pharma, Inc.’s Form 10-Q for the three months ended September 30, 2013, not a filing identified as Lite Strategy, Inc. or 2012 Q1. Investors should verify the issuer and period before relying on this summary. MEI Pharma describes itself as a development-stage oncology company; it reported no revenue in the presented quarter.
Its pipeline included Pracinostat, in Phase II development for hematologic cancers; ME-344 and ME-143; and PWT143, acquired in September 2013 and in preclinical development. The company reported 21,493,405 common shares outstanding as of November 6, 2013.
Financial performance and position
Amounts below are in U.S. dollars; financial statement figures are presented in thousands unless otherwise noted.
| Metric | Quarter ended September 30, 2013 | Comparable 2012 quarter / prior balance date |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $3.102 million | $1.552 million |
| General and administrative expense | $1.811 million | $0.914 million |
| Total operating expenses | $4.913 million | $2.466 million |
| Net loss | $4.896 million | $2.464 million |
| Net loss per share, basic and diluted | $0.29 | $0.70 |
| Operating cash flow | $(4.063) million | $(2.487) million |
| Cash and cash equivalents | $31.504 million | $35.573 million at June 30, 2013 |
| Total current assets / current liabilities | $32.106 million / $1.465 million | $36.029 million / $1.675 million at June 30, 2013 |
| Total assets / stockholders’ equity | $32.617 million / $31.152 million | $36.547 million / $34.872 million at June 30, 2013 |
The company reported no debt balance in the supplied balance sheet. The current ratio was approximately 21.9 at quarter-end. Gross and operating margins are not meaningful because no revenue was reported. Cash declined by $4.069 million during the quarter; investing cash use was $6,000 and there was no financing cash flow.
Material changes versus the prior comparable period
- Net loss approximately doubled year over year, while operating expenses increased by $2.447 million.
- R&D expense rose by $1.550 million, mainly due to Pracinostat manufacturing and Phase II trial costs, ME-344 Phase I costs, and increased personnel and share-based compensation.
- G&A expense rose by $897,000; the filing attributes the increase primarily to higher salaries and benefits, including share-based compensation.
- Quarter-end cash was $4.069 million below its June 30, 2013 balance. The 2012 comparison cash balance at September 30 was $3.713 million.
Outlook, commentary, risks and unusual items
- Management expected the September 30 cash balance plus approximately $32.7 million of net proceeds from an October 30, 2013 offering to fund operations through calendar 2015. The offering sold 4.375 million shares at $8.00 per share for $35 million gross proceeds. This runway estimate is subject to changes in development plans and operating costs; management anticipated possible future capital raising.
- Management expected R&D expense to increase in fiscal 2014, primarily due to Pracinostat Phase II trials. The company anticipated completing enrollment in a 100-patient Pracinostat/azacitidine Phase II trial by June 2014 and topline data in December 2014. It expected to initiate an ME-344 Phase Ib trial in the second quarter of calendar 2014 and target an IND filing for PWT143 by the end of 2014.
- ME-344 Phase I results presented in October 2013 included a confirmed partial response in one patient and prolonged progression-free survival in some patients. The filing also reports dose-limiting Grade 3 peripheral neuropathy at higher dose levels, and individual cases of angina and QTc prolongation.
- Risks highlighted include clinical-trial failure or delay, regulatory uncertainty, need for additional financing, dependence on third-party development and supply arrangements, competition, and intellectual-property risks. The company had accumulated losses of approximately $101.2 million and expected continuing operating losses and negative operating cash flow.
- The S*Bio asset agreement provides for potential milestone payments of up to $75.2 million, plus contingent sales-based earnouts; the first stated milestone is triggered by first dosing in a Phase III or other pivotal trial. No amount had been accrued for potential future payments at September 30, 2013. CyDex terms include future milestones and low-single-digit royalties on sales of approved drugs using Captisol.
- Share-based compensation was $1.176 million for the quarter, compared with $90,000 in the prior-year quarter. The filing also reports substantial unrecognized compensation expense on outstanding options and RSUs.
Most important facts to verify
- Confirm the issuer and reporting period: the supplied document identifies MEI Pharma and the quarter ended September 30, 2013, inconsistent with the request metadata.
- Verify the October 2013 offering’s net proceeds and whether management’s projected funding runway through 2015 remains applicable.
- Track trial enrollment, timing, and outcomes for Pracinostat and ME-344, and progress toward the PWT143 IND filing.
- Assess the clinical safety findings, potential S*Bio milestones and earnouts, and CyDex milestone and royalty obligations.
- Monitor cash burn, rising development costs, and the potential need for further financing and dilution.